Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.

Diabetes research and clinical practice - 1 Dec 2009

van Genugten Renate E, van Raalte Daniël H, Diamant Michaela

Abstract excerpt

Type 2 diabetes (T2DM) is a heterogeneous syndrome, characterized by beta-cell failure in the setting of obesity-related insulin resistance. T2DM has a progressive course and is associated with a high cardiovascular disease (CVD) risk, regardless of the treatment used. The incretin hormones gluca...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Glucagon
Share to Glucagon-Like Peptide 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Hypoglycemic Agents

Share to Insulin-Secreting Cells

Share to Peptides

Share to Receptors, Glucagon

Source

Identifiers

PMID: 20115929
DOI: 10.1016/S0168-8227(09)70006-3

Genes

GIP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20115929-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.PMID 20115929Read ↗

Recent advances in understanding the role of glucagon-like peptide 1Semantic proximity Read ↗

A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated ComorbiditiesSemantic proximity Read ↗

Pathophysiology of type 2 diabetes: targeting islet cell dysfunction.Semantic proximity Read ↗

A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulationSemantic proximity Read ↗

A review of nateglinide in the management of patients with type 2 diabetes.Semantic proximity Read ↗

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)Semantic proximity Read ↗

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectivenessSemantic proximity Read ↗

The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive ReviewSemantic proximity Read ↗

Application of microRNAs in diabetes mellitusSemantic proximity Read ↗

Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function.Semantic proximity Read ↗

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort studySemantic proximity Read ↗

Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.